Creative Medical Technology Holdings announced positive data and filing of a patent application covering the use of ImmCelz? in prevention and regression of type 1 diabetes.

In a series of experiments using the non-obese diabetic model, administration of ImmCelz? was able to reduce incidence of diabetes, but also to reverse diabetes in several mice. Molecular analysis revealed that ImmCelz? administration was associated with increase production of regenerative cytokines such as VEGF, EGF, IGF, and HGF, all of which have been implicated in regeneration of damaged pancreatic tissues.

"More than 10 years ago, together with my collaborators, we have demonstrated ability to modulate destruction of, and even regenerate, pancreatic tissue by utilization of various cellular therapies," said Thomas Ichim, Ph.D, and co-inventor of the patent. "To be able to induce production of the pancreas from autoimmunity by utilization of immune based regenerative technologies is, to my knowledge, a completely new and promising area of addressing the issue of type 1 diabetes."

"The data disclosed today support the possibility that ImmCelz? truly is a form of 'regenerative immunotherapy,' " said Dr. Amit Patel, co-inventor of the patent. "To my knowledge this is the first cellular therapy in which immune cells, particularly T cells, are programmed by coculture with umbilical cord stem cells to generate a product that actually induces production of regenerative cytokines in vivo."

"The ongoing influx of positive experimental data supports the notion that ImmCelz? is a promising therapeutic platform that has ability to address many unmet medical needs associated with degeneration and inflammation," said Timothy Warbington, President and CEO of the Company. "Our vision is that one day ImmCelz? will be for degenerative diseases what CAR-T cells were for hematology."